Current chemo-treatments and protocols for breast cancer management
New York, NY, United States 2019
Current chemo-treatments and protocols for breast cancer management
Neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and an Oncotype Dx Recurrence Score (≤25)
San Antonio, TX, United States 2019
Neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and an Oncotype Dx Recurrence Score (≤25)
Cost-effectiveness of different neoadjuvant followed by adjuvant treatment combination strategies for women with HER2-positive breast cancer
San Antonio, TX, United States 2019
Cost-effectiveness of different neoadjuvant followed by adjuvant treatment combination strategies for women with HER2-positive breast cancer
Adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis
San Antonio, TX, United States 2019
Adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis
Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE
San Antonio, TX, United States 2018
San Antonio Breast Cancer Symposium
Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC)
Chicago, IL, United States 2018
American Society of Clinical Oncology, Annual Meeting
An Evening Symposium on Breast Cancer – Incorporating Emerging Practice Options for HER2 and ER+ Breast Cancer
Tampa, FL, United States 2017
An Evening Symposium on Breast Cancer – Incorporating Emerging Practice Options for HER2 and ER+ Breast Cancer
Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fouorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer
Chicago, IL, United States 2017
American Society of Clinical Oncology, Annual Meeting
Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (dd AC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): A phase I/II trial
Chicago, IL, United States 2017
American Society of Clinical Oncology, Annual Meeting
Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?
Westwood, KS, United States 2017
Southwestern Surgical Congress, Annual Meeting
A novel approach to the medical student hematology curriculum
San Diego, CA, United States 2016
American Society of Hematology, Annual Meeting
Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study
Chicago, IL, United States 2016
American Society of Clinical Oncology, Annual Meeting
Development of an interactive text messaging tool to improve adherence with adjuvant endocrine therapy: Breast Cancer Endocrine Therapy Adherence (BETA) Pilot Study
San Antonio, TX, United States 2015
San Antonio Breast Cancer Symposium
Review of trends in adjuvant chemotherapy regimens in breast cancer over 10 year period at Yale New Haven Hospital (YNHH)
San Francisco, CA, United States 2015
American Society of Clinical Oncology Breast Cancer Symposium
A phase II trial of neoadjuvant aromatase inhibitor therapy and the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and a low/intermediate risk Oncotype Dx Recurrence Score (≤ 25)
Chicago, IL, United States 2015
American Society of Clinical Oncology, Annual Meeting
Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy
Chicago, IL, United States 2015
American Society of Clinical Oncology, Annual Meeting
Mutation-based treatment recommendations from next generation sequencing data: A comparison of web tools
Chicago, IL, United States 2015
American Society of Clinical Oncology, Annual Meeting
Patient preferences for disclosure of incidental genetic information discovered through high-throughput sequencing
Philadelphia, PA, United States 2015
American Association for Cancer Research, Annual Meeting
Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors
Chicago, IL, United States 2014
American Society of Clinical Oncology, Annual Meeting
Training medical students and faculty to have constructive feedback discussions about courses
New Haven, CT, United States 2014
Northeastern Group on [Medical] Educational Affairs, Spring Annual Rretreat
Predictors of Use of Adjuvant Chemotherapy and Overall Survival Outcomes in Elderly Breast Cancer Patients
Phoenix, AZ, United States 2014
Society of Surgical Oncology Cancer Symposium
Characterization of the relationship between pathologic complete response from neoadjuvant treatment and survival measures in breast cancer subtypes: Implications for study design
San Antonio, TX, United States 2013
San Antonio Breast Cancer Symposium
Patterns of the use of primary systemic therapy in the United States
San Antonio, TX, United States 2013
San Antonio Breast Cancer Symposium
Follow up of breast cancer patients who underwent gamma knife radiosurgery for a diagnosis of brain metastases: A single institutional experience
San Antonio, TX, United States 2013
San Antonio Breast Cancer Symposium
Baseline assessment of left ventricular function for breast cancer patients undergoing anthracycline and/or trastuzumab therapy
San Antonio, TX, United States 2013
San Antonio Breast Cancer Symposium
The impact of survivorship care plans on knowledge among breast cancer survivors
San Francisco, CA, United States 2013
American Society of Clinical Oncology Breast Cancer Symposium
Quantitative Ki-67 score as predictive of response to neoadjuvant chemotherapy in breast cancer
Chicago, IL, United States 2013
American Society of Clinical Oncology, Annual Meeting
Multicenter phase II trial of neoadjuvant carboplatin, weekly nab-paclitaxel, and trastuzumab in stage II-III HER2+ breast cancer: A BrUOG study
Chicago, IL, United States 2013
American Society of Clinical Oncology, Annual Meeting
Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer
Chicago, IL, United States 2013
American Society of Clinical Oncology, Annual Meeting
Neoadjuvant weekly nap-paclitaxel (wA), carboplatin (Cb) plus bevacizumab (B) with or without dose-dense doxorubicin-cyclophosphamide (ddAC) + B in ER+/HER2-negative (HR+) and triple-negative (TN) breast cancer (BrCa): a BrUOG study
Chicago, IL, United States 2012
American Society of Clinical Oncology, Annual Meeting
A phase I study of biweekly capecitabine and the histone deacetylase inhibitors (HDACi) vorinostat in advanced breast cancer (BC)
Chicago, IL, United States 2011
American Society of Clinical Oncology, Annual Meeting
Exploring a Therapeutic Role for IGF1R Inhibitors in Triple-Negative Breast Cancer
San Antonio, TX, United States 2010
San Antonio Breast Cancer Symposium
Trastuzumab (H) and Rapamycin (R) for treatment of HER-2 overexpressing metastatic breast cancer (BC) with prior disease progression on H based therapy: Safety and pharmacodynamic (PD) results
San Antonio, TX, United States 2010
San Antonio Breast Cancer Symposium
Evaluation of the mechanism of action of histone deacetylase inhibitors (HDACi) in the treatment of breast cancer (BC)
Hollywood, FL, United States 2010
ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer
Self-Management and Transitions in Palliative Care
Quebec City, QC, Canada 2010
18th International Congress on Palliative Care
Therapeutic Targeting of the Interactions Between Hormone and Growth Factor Receptor Signaling
Troy, NY, United States 2010
New Frontiers in Breast Cancer Research and Prevention
A phase Ι study of the mTOR inhibitor sirolimus (Rapamycin, R) in combination with nanoparticle albumin-bound paclitaxel (nab-P)
Chicago, IL, United States 2010
American Society of Clinical Oncology Annual Meeting
Blocking Cross-Talk Between ER and Growth Factor Pathways
New York, NY, United States 2009
Physicians’ Education Resource, Eighth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant
What is breast cancer?
West Haven, CT, United States 2009
"Hope, Not Fear", Fourth Annual Breast Cancer Community Forum
Association between HER2/neu overexpression and calcifications in breast cancer
Orlando, FL, United States 2009
American Society of Clinical Oncology, Annual Meeting
Histologic subtypes of ductal intraepithelial neoplasia (DIN) of the breast: Characteristic associations and biology
Orlando, FL, United States 2009
American Society of Clinical Oncology, Annual Meeting
Insulin-like Growth Factor Receptor: Role in Breast Cancer
Riyadh, Riyadh Province, Saudi Arabia 2008
First Saudi Oncology Society International Breast Cancer Conference
Breast cancer
Riyadh, Riyadh Province, Saudi Arabia 2008
Medical Files
What is breast cancer?
West Haven, CT, United States 2008
"Hope, Not Fear", Third Annual Breast Cancer Community Forum
Neoadjuvant chemotherapy decreases the need for re-excision of breast cancers between 2 and 4 cm diameter
Chicago, IL, United States 2008
Society of Surgical Oncology Annual Cancer Symposium
Breast sentinel lymph node dissection (SLND) prior to preoperative chemotherapy
Colorado Springs, CO, United States 2007
Western Surgical Association Annual Meeting
Metastatic breast cancer
North Haven, CT, United States 2007
CTV Television Program
Pre-clinical studies of combination targeted therapies in breast cancer
New Brunswick, NJ, United States 2007
Cancer Center Grand Rounds
Chemotherapy and Hormonal Therapy Advances in Breast Cancer
Stamford, CT, United States 2006
Physicians’ Education Resource, Emerging Trends in Oncology: Updates from 2006 AACR and ASCO Meetings
Neoadjuvant dose-dense (DD) concurrent doxorubicin (A) and docetaxel (T) for stage III breast cancer (BC)
Atlanta, GA, United States 2006
American Society of Clinical Oncology, Annual Meeting
Combinations of drugs that block HER2, ER and IGF1R
Hartford, CT, United States 2006
Susan G. Komen Breast Cancer Foundation, “Breast Cancer: Survive and Conquer” Symposium
Combinations of HER2, estrogen receptor (ER) and IGF-I receptor (IGF1R) inhibitors induce apoptosis in breast cancer cells: Dramatic effects of HER2 inhibitors on non-overexpressing cells
Washington, DC, United States 2006
American Association for Cancer Research, Annual Meeting
Herceptin as Adjuvant Therapy: A Dramatic Leap Forward in Improving the Cure Rate of Breast Cancer
New Haven, CT, United States 2005
Y-ME National Breast Cancer Organization, Connecticut Affiliate, Annual Breast Cancer Symposium
Targeting the HER2-ER cross-talk in breast cancer
Sunnybrook, AB, Canada 2004
Sunnybrook Regional Cancer Centre Grand Rounds
Comparison of HER-2 and topoisomerase II amplification with outcome after cyclophosphamide, doxorubicin and 5 FU-based chemotherapy for Stage II breast cancer (CALGB 8541/150013)
New Orleans, LA, United States 2004
American Society of Clinical Oncology, Annual Meeting
Synergistic interactions between all-trans retinoic acid, Herceptin, and tamoxifen in BT-474 human breast cancer cells
Orlando, FL, United States 2004
American Association for Cancer Research, Annual Meeting
Targeting HER2 and ER in breast cancer
Key Biscayne, FL, United States 2003
American Cancer Society – Harry and Elsa Jiler-American Cancer Society Professors Meeting
Phosphorylated/activated HER2 (P-HER2) as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer (MBC)
Washington, DC, United States 2003
American Association for Cancer Research, Annual Meeting
Antitumor activity of combinations of tamoxifen and Herceptin in BT-474 human breast cancer cells
Washington, DC, United States 2003
American Association for Cancer Research, Annual Meeting
Adjuvant sequential dose dense doxorubicin, paclitaxel and cyclophosphamide (ATC) for high risk breast cancer (BC)
Chicago, IL, United States 2003
American Society of Clinical Oncology, Annual Meeting
Activated (phosphorylated) HER-2/neu in breast cancer
New York, NY, United States 2002
The Society for Applied Immunohistochemistry Symposium
Use of Herceptin in breast cancer
Jasper, AB, Canada 2002
The North Alberta Breast Cancer Program Symposium
Management Options in Metastatic Breast Cancer
New York, NY, United States 2002
Centralized Tumor Conference/Grand Rounds
Update on HER-2/neu: Clinical implications, Importance of Testing, Activated HER-2/neu
Ottawa, ON, Canada 2002
Ottawa Regional Cancer Centre Grand Rounds
Update on HER-2/neu: Clinical implications, Importance of Testing, Activated HER-2/neu
Kingston, ON, Canada 2002
Kingston Regional Cancer Centre Lecture
Activation state of HER-2/neu: Clinical implications
Boston, MA, United States 2001
Dana-Farber Cancer Institute Breast Cancer Conference
Activation state of HER-2/neu: Clinical implications
Toronto, ON, Canada 2001
Greater Toronto Area Breast Cancer and Lymphoma Update
Activation state of HER-2/neu: Clinical implications
Calgary, AB, Canada 2000
Tom Baker Cancer Centre Grand Rounds
Activation state of HER-2/neu: Clinical implications
Scottsdale, AZ, United States 2000
The Canadian Oncology Leaders Conference
The prognostic value of molecular marker expression in oral and oropharyngeal squamous cell carcinoma
San Francisco, CA, United States 2000
The 5th International Conference on Head and Neck Cancer
Signaling status of HER-2/neu as a prognostic factor in breast cancer
Atlanta, GA, United States 2000
Annual Meeting, The Department of Defense Breast Cancer Research Program Meeting
Signaling status of HER-2/neu as a prognostic factor in breast cancer
Atlanta, GA, United States 2000
The Department of Defense Breast Cancer Research Program, Annual Meeting
Update on HER-2/neu: Clinical implications, Importance of Testing, Activated HER-2/neu
Meriden, CT, United States 2000
Midstate Medical Center, John M. McIntyre Symposium
Synergistic interactions between tamoxifen and HerceptinTM
San Francisco, CA, United States 2000
American Association for Cancer Research, Annual Meeting
Update on HER-2/neu: Clinical implications, Importance of Testing, Activated HER-2/neu
Norwalk, CT, United States 2000
Norwalk Hospital Cancer Center, Breast Cancer Conference
ErbB-2, activated ErbB-2 and EGFR immunoexpression in breast cancers
San Antonio, TX, United States 1999
San Antonio Breast Cancer Symposium
Activation state of HER-2/neu: Clinical implications
New Orleans, LA, United States 1999
American Society of Clinical Pathologists Meeting
Breast cancer update
Glastonbury, CT, United States 1999
The Claire C. Courtney Breast Cancer Foundation
Activated erbB-2 immunodetection using PN2A: Biologic and prognostic associations
San Antonio, TX, United States 1998
San Antonio Breast Cancer Symposium
How Breast Cancer Arises
New Haven, CT, United States 1998
Y-ME National Breast Cancer Organization, Connecticut Affiliate, Annual Breast Cancer Symposium
Pattern of tyrosine phosphorylation of Neu (HER-2/erbB-2) provides a model for breast tumorigenesis in transgenic mice
New Orleans, LA, United States 1998
American Association for Cancer Research, Annual Meeting
Activation of HER-2/neu in breast cancer
Washington, DC, United States 1997
The Department of Defense Breast Cancer Research Program, Annual Meeting
Activation state of HER-2/neu: Clinical implications
Davis, CA, United States 1997
University of California, Davis, Oncology Grand Rounds
Functional assay for HER-2/neu in invasive breast carcinoma demonstrates active signaling in a minority of cases with HER-2/neu overexpression. Clinicopathologic correlations.
Washington, DC, United States 1996
American Association for Cancer Research, Annual Meeting
Activation State Specific Anti-p185neu/erbB2 Monoclonal Antibody Detects the Phosphorylated Receptor in Breast Tumors
Toronto, ON, Canada 1995
American Association for Cancer Research, Annual Meeting
Myeloid Differentiation Associated Protein Tyrosine Kinase Activity in a Murine Monomyelocytic Leukemia Cell Line
San Francisco, CA, United States 1989
American Association for Cancer Research, Annual Meeting
Measurement of Cytotoxicity and DNA Crosslinks Induced by Mitomycin C (MC) and MC-analogs in Aerobic and Hypoxic EMT6 Cells
New Orleans, LA, United States 1988
American Association for Cancer Research, Annual Meeting
In Vivo Effects of Recombinant Granulocyte-Macrophage Colony Stimulating Factor (rGM-CSF) in Cyclophosphamide (CTX) Treated Mice
New Orleans, LA, United States 1988
American Association for Cancer Research, Annual Meeting